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Abstract
Background: To assess the efficacy of salvage radiotherapy (RT) for persistent or rising PSA after
radical prostatectomy and to determine prognostic factors identifying patients who may benefit
from salvage RT.
Methods: Between 1990 and 2003, 59 patients underwent RT for PSA recurrence after radical
prostatectomy. Patients received a median of 66 Gy to the prostate bed with 3D or 2D RT. The
main end point was biochemical failure after salvage RT, defined as an increase of the serum PSA
value >0.2 ng/ml confirmed by a second elevation.
Results: Median follow-up was 38 months. The 3-year and 5-year bDFS rates were 56.1% and
41.2% respectively. According to multivariate analysis, only preRT PSA ≥1 ng/ml was associated
with biochemical relapse.
Conclusion: When delivered early, RT is an effective treatment after radical prostatectomy. Only
preRT PSA ≥1 ng/ml predicted relapse.
Background
In Europe, the estimated incidence of prostate cancer is
238,000 new cases with 85,000 deaths per year [1]. Radi-
cal prostatectomy is the most widely used treatment for
localized prostate cancer. Unfortunately, local recurrences
occur in up to one-third of the patients by 5 years after sur-
gery. It is generally accepted that 30% (27–32%) of all
patients by 10 years after surgery suffer biochemical
relapse, defined as increasing serum prostate-specific anti-
gen (PSA) levels >0.2 ng/ml [2,3]. PSA relapse exposes to
a 34% risk of metastatic disease at 5 years. After metastatic
relapse, median survival is 5 years [4].
"Salvage" radiotherapy (RT) to the prostate bed for bio-
chemical relapse achieved biochemical control in
10–66% of the patients at 5 years [5,6]. PSA failure after
prostatectomy could reflect local relapse or metastatic dis-
ease. At present, modern imaging techniques lack the sen-
sitivity to differentiate between these two types of relapse.
Identification of the best candidates for RT should be
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based on factors predictive for local relapse. Numbers of
positive margins, low Gleason score and/or long PSA-
doubling time have been proposed to select patients for
RT, but they are still discussed [7].
In this study, we evaluated RT efficacy and determine
prognostic factors identifying patients who may benefit
from salvage RT.
Methods
We reviewed the records of 59 patients who underwent RT
between 1990 and 2003 for biochemical relapse of pros-
tate cancer initially treated with radical prostatectomy. All
patients had persistent or rising PSA >0.20 ng/ml at some
time after surgery. None had imaging (bone scan and/or
abdominal-pelvic computed tomography (CT) Scan) or
clinical evidence of metastases at the time of the biochem-
ical relapse.
A number of potential predictive factors were recorded:
initial PSA (before surgery); age at the time of the surgery;
T stage; margin status (6 sides); seminal vesicle involve-
ment or extracapsular invasion; surgical Gleason score;
perineural invasion; PSA nadir after surgery; PSA-dou-
bling time (PSA DT) between surgery and RT calculated as
follows: Ln 2 × (t2 - t1)/[Ln (PSA t2) - Ln (PSA t1)] [8];
PSA before RT (preRT PSA) and interval between surgery
and RT.
RT delivered to the prostate bed a median of 66 Gy in 2.2
Gy daily fractions, four days per week, with 18 MV photon
beams. Between 1990 and 1998, classical 2D RT was
administered using a four-field box technique to 22
(37.3%) patients with fields of 10 cm × 10 cm shaped to
protect small bowel, portions of the bladder and posterior
rectal wall. The fields encompassed the prostatic/seminal
vesicle bed and periprostatic tissues. Pelvic lymph nodes
were not irradiated. After 1998, conformational 3D RT
was adopted to define optimally the clinical target volume
(CTV) and organs at risk (bladder and rectum). CTV
included the prostatic/seminal bed, with a security margin
to encompass subclinical disease in the periprostatic area.
The planning target volume (PTV) was defined by extend-
ing the CTV 0.5 cm posteriorly and 1 cm in all other direc-
tions. No elective nodal irradiation was performed. Dose
Volume Histograms were performed to decrease the dose
at organs at risk. Treatment-related toxicity was graded
according to the Radiation Therapy Oncology Group
(RTOG) criteria [9] and the Expanded Prostate-cancer
Index Composite (EPIC) score for urinary incontinence
[10].
After radiation, patients were followed every 6 months by
a radiation oncologist and a urologist with physical exam-
ination and PSA analysis. Imaging to exclude metastastic
disease was performed at the physician's discretion, as was
the prescription of hormone therapy for biochemical or
clinical failure after RT. The interval between surgery and
hormone therapy after RT failure was also recorded.
Biochemical failure after salvage RT was defined as an
increase of the serum PSA value >0.2 ng/ml confimed by
a second elevation.
Clinical failure was defined as evidence of clinical, sono-
graphic, radiographic, or scintigraphic recurrence. The pri-
mary end point was biochemical relapse or introduction
of hormone therapy before the criteria of PSA recurrence
or clinical failure before biochemical relapse were met.
The other end points were overall and specific survival
rates.
Statistical analysis
Survival curves were plotted using the Kaplan-Meier
method. Survival rates were calculated from the last day of
RT. The date of failure was defined at the time of the bio-
chemical failure.
Patients who biochemically had no evidence of disease
(bNED) were censured at the time of last follow-up.
Univariate and multivariate analysis using a Cox propor-
tional hazards regression analysis were conducted to iden-
tify significant predictors of biochemical outcome for
several clinical and pathological factors: pre surgery PSA;
Gleason score; high-grade histological differentiation (4
or 5); extra prostatic extension (capsule or seminal vesicle
invasion); positive surgical margin(s); ≥3 positive surgical
margins; lymphovascular invasion; short PSA DT ≤12
months; persistently high PSA after surgery (>0.2 ng/ml);
preRT PSA ≥0.5, ≥1 or ≥2 ng/ml; surgery-RT interval; dura-
tion of RT; classical 2D or 3D RT.
For all analyses, the level of significance was set at 0.05.
Statistical analysis was performed using Statview software.
Results
Patient characteristics
Patient and tumor characteristics are reported in Table 1.
Fifty-nine patients were treated within a 13-year interval.
It should be noted that 11 (18.6%) patients had no
lymph-node dissection at the time of radical prostatec-
tomy and did not receive any lymph-node irradiation at
the time of RT. One (2%) patient had a nodal involve-
ment at the time of RT. Seven patients (12%) received
short-term (≤6 months) hormonetherapy, with Luteiniz-
ing Hormone Releasing Hormone agonist, after surgery, at
the urologist's discretion.BMC Cancer 2008, 8:26 http://www.biomedcentral.com/1471-2407/8/26
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Thirty-five patients had positive margins but no mention
of margin status was made in one patient's report.
RT was delivered to 80% of the patients because of a rising
PSA levels after postoperative negativity and for persist-
ently high PSA after surgery for the remaining 20%. 3D
and 2D salvage RT was performed in 63% and 37% of the
patients, respectively. The median RT dose delivered was
66 Gy (59.4–70.4) in a mean of 60 days.
Survival and bDFS
Median follow-up was 38 months after completing RT. At
3 years, the overall and specific survival rates were 93%
and 100% respectively. The estimated 5-year overall sur-
vival rate was 87% and specific survival was 96%.
bDFS at 3 years was 56.1%. The estimated 5-year bDFS
was 41.2% (Figure 1).
Prognostic factors for bDFS
Biochemical control was analyzed using different preRT
PSA thresholds (from <0.5 to ≥2 ng/ml) (Figure 2):
patients with preRT PSA <0.5 or [0.5–1]ng/ml had compa-
rable bDFS rates ≈70% while those with PSA of [1–2] or
≥2 ng/ml had ≈30% bDFS at 3 years. The bDFS rates for
these different PSA thresholds were significantly different
(p = 0.008). PreRT PSA of 1 ng/ml was the most signifi-
cant threshold that could distinguish patients with good
or bad biochemical control after RT: PSA <1 ng/ml was
associated with a 3-year bDFS of 68.3% compared to
30.1% for PSA ≥1 ng/ml (p = 0.0006) (Figure 3).
PreRT PSA ≥1 (p = 0.001) or 2 ng/ml (p = 0.04) and not
Gleason score or margin status, in particular, were associ-
ated with poor 3-year bDFS outcome (Table 2). Multivar-
iate analysis retained only preRT PSA ≥1 ng/ml as
independently predictive of biochemical failure.
Comparisons of bDFS after the end of RT according to dif- ferent preRT PSA thresholds Figure 2
Comparisons of bDFS after the end of RT according 
to different preRT PSA thresholds. PSA < 0.5 ng/ml( ) 
vs. [0.5–1] ng/ml() vs. [1–2] ng/ml(Δ) vs. ≥2 ng/ml().
 
Table 1: Characteristics of the 59 men who underwent RT for 
PSA relapse after radical prostatectomy
Characteristic patients, n Values
Age, median [range] 62 [46-76] years
Preoperative PSA, median [range] 16.7 [1-60] ng/ml
pTNM stage, n (%)
pT2a 2 (3.4)
pT2b 1 (1.7)
pT2c 22 (37.3)
pT3a 20 (33.9)
pT3b 14 (23.7)
pN- 47 (79.7)
pN+ 1 (1.7)
pNx 11 (18.6)
Gleason score, n (%)
3–6 12 (20.3)
7* 30 (50.9)
3+4 13 (23.6)
4+3 13 (23.6)
8 7 (11.9)
9 10 (16.9)
Positive surgical margins†, n (%) 35/58 (60.3)
Minimal <3 19/34 (55.9)
Extensive ≥3 15/34 (44.1)
Perineural invasion, n (%) 40/46 (87)
Detectable PSA after surgery, n (%) 12 (20.3)
PSA rise after postsurgical negativity, n (%) 47 (79.7)
PSA doubling time, median 12.9 months
PSA nadir preRT, median 0.4 ng/ml
PSA level preRT, median 1.43 ng/ml
Surgery to RT interval, median 26 months
* Score composition not detailed for 4 patients.
bDFS after the end of RT according to PSA >0.2 ng/ml defini- tion Figure 1
bDFS after the end of RT according to PSA >0.2 ng/ml defini-
tion.
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Treatment tolerance
Late rectal toxicity (grade ≥2) was seen in seven patients
treated with 2D RT (2 grade 3 and 2 grade 4) versus 8 with
3D RT (1 grade 3 and 0 grade 4).
Severe (grade ≥2) late urinary tract complications (stric-
ture, hematuria) were observed in 3 patients who received
2D RT versus 1 given 3D RT, with 1 grade 3 and 0 grade 4
for each technique. Urinary incontinence (EPIC grade ≥2)
developed in 2 patients given 2D RT and 4 with 3D RT.
Discussion
We obtained a 3- and 5-year bDFS of 56.1% and 41.2%
respectively, which are comparable to most of those pre-
viously reported for prostate cancer patients given RT after
prostatectomy [11-31] (Table 3).
Table 3: Published series of salvage radiotherapy for biochemical failure after radical prostatectomy
Investigator Year of publication Patients (n) Median Follow-up (months) Freedom from Biochemical Relapse
Anscher [11] 2000 89 48 50% at 4 years
Peschel [12] 2000 39 - 27% at 3 years
Pisansky [13] 2000 166 52 46% at 5 years
Catton [14] 2001 59 44 48% at 3 years
Koppie [15] 2001 67 36 44% at 3 years
Leventis [16] 2001 49 29 43% at 3 years
Vanuytsel [17] 2001 53 36 46% at 3 years
Chawla [18] 2002 54 45 35% at 5 years
De la Taille [19] 2002 52 28 51% at 3 years
Do [20] 2002 73 87 45% at 10 years
Kalapurakal [21] 2002 41 31 57% at 5 years
Song [22] 2002 61 36 39% at 4 years
Liauw [23] 2003 51 46 56% at 3 years
Peyromaure [24] 2003 62 44 42% at 5 years
Taylor [25] 2003 44 35 66% at 5 years
Mc Donald [26] 2004 102 50 38% at 5 years
Stephenson [27] 2004 501 45 50% at 45 months
Patel [28] 2005 48 16 62.5% at 16 months
Buskirk [29] 2006 368 60 46% at 5 years
Neuhof [30] 2007 171 39 35% at 5 years
Stockdale [31] 2007 32 30 56% at 30 months
Current study - 59 38 56% at 3 years
Table 2: Prognostic factors of bDFS after salvage RT at 3 years 
(PSA > 0.2 ng/ml definition), univariate analysis
3-year bDFS (%)
Criterion Yes No p-value
Presurgical PSA ≥10 58.2 48.2 0.8
Gleason score ≥8 40.3 65.2 0.2
High grade (≥4) 52.2 87.5 0.3
pT3 46.9 69.2 0.08
pT3b 41.7 60.7 0.2
Positive margin(s) 47.7 61.4 0.3
≥3 positive margins 58.3 58.8 0.7
Perineural invasion 48.3 83.3 0.8
PSA DT ≤12 months 58.8 51.9 0.8
No PSA negativity 48.6 58.2 0.2
PreRT PSA ≥2 ng/ml 33 60.9 0.04
PreRT PSA ≥1 ng/ml 30.1 68.3 0.001
Surgery-RT interval (≤12 months) 36.6 54.8 0.4
RT duration (≥60 days) 54 57.5 1.0
Classical 2D RT 70 45.7 0.2
PSA: Prostate specific antigen; DT: doubling time; RT: radiotherapy.
Comparison of bDFS after the end of RT according to 1 ng/ ml preRT PSA threshold Figure 3
Comparison of bDFS after the end of RT according 
to 1 ng/ml preRT PSA threshold. PSA ≥1 ng/ml( ) vs. <1 
ng/ml().
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Poorer prognoses, in terms of bDFS after RT, were previ-
ously associated with mainly: higher preRT PSA values,
high-grade disease, and seminal vesicle involvement [13-
27]. Indeed, for our 59 patients, preRT PSA was associated
with biochemical relapse after RT.
High preRT PSA was associated with poor biochemical
control after RT regardless of the biochemical definition
used. This observation is consistent with the previously
reported finding that preRT PSA was the most frequently
selected factor predictive of bDFS [5-31]. Those authors
described poorer prognoses associated with higher PSA
values before RT using thresholds ranging from 0.4 to 2
ng/ml. An ASTRO consensus panel recommended that RT
be delivered before the PSA level reaches 1.5 ng/ml [32].
For our patients with a preRT PSA <1 ng/ml, the 3-year
bDFS was significantly higher than for those with a PSA ≥1
ng/ml (70 vs 30% respectively). We analyzed 3-year bDFS
as a function of different preRT PSA thresholds: rates
declined as PSA concentrations increased from <0.5
(66.4%) to ≥2 ng/ml (only 33%). These significantly dif-
ferent rates (p = 0.008) are strong arguments supporting
early treatment after biochemical relapse. We think that,
in the setting of RT, the earlier the better. When biochem-
ical failure is confirmed, and a sufficient number of factors
suggestive of local relapse are present, patients should be
irradiated without waiting for PSA to reach 1 or 1.5 ng/ml.
Recently, the randomized EORTC 22911 study demon-
strated significant improvement for adjuvant RT vs salvage
RT in terms of bDFS and clinical local control at 5 years
but not for overall survival [33]. Similarly, adjuvant RT
significantly increased bDFS vs observation in the ARO
96-02 and the SWOG 8794 studies [34,35]. But adjuvant
RT based only on unfavorable histological prognostic fea-
tures (positive surgical margins, seminal vesicle involve-
ment or extra capsular effraction) would expose some of
these patients to over treatment with the risk of inconti-
nence and urethral stricture resulting from the accumula-
tion of the two treatments. Indeed 40–50% of the patients
with positive surgical margins would develop biochemi-
cal relapses at 5-years [36,37]. To conclude definitively,
we should compare adjuvant radiotherapy vs early salvage
radiotherapy: GETUG and RADICALS ongoing trials will
try to answer to this question.
Gleason score and high grade prostate cancer was associ-
ated with poor biochemical outcome in previous reported
studies [19-30]. However, we did not find any significant
bDFS difference for patients with a low (≤6) or high (≥7)
Gleason scores. Seminal vesicle involvement or margin
status was also previously associated with poorer out-
come.
In this study, we did not observe any difference in terms
of incontinence (grade ≥2) according to EPIC score or rec-
tal toxicity (grade ≥2) between salvage 3D and 2D RT. Uri-
nary tract toxicities (stricture, hematuria) were also similar
for the two techniques, with very low frequencies in both
groups which is consistent with the MSKCC experience, in
which adjuvant/salvage 3D RT was associated with 5%
grade ≥2 toxicity [38].
Conclusion
Salvage RT is an effective treatment after radical prostatec-
tomy. bDFS 3- and 5-years after salvage RT were 56% and
41%, respectively. RT was well tolerated in terms of uri-
nary toxicity, especially with 3D RT. PreRT PSA was the
most powerful prognostic of bDFS before RT delivery and
surpassed all other factors evaluated. To increase its effi-
cacy, RT should be given earlier after biochemical relapse,
ideally when preRT PSA <1 ng/ml, to obtain the best bio-
chemical control.
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